Myovant Sciences Ltd(NYSE:MYOV) 
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antago...
Website: http://myovant.com
Founded: 2016
Full Time Employees: 407 (May 2021)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2022-09-09
P
O 19.51
H 20.23
L 19.24
C 19.82
V 907,724
10EMA 19.82
20EMA 19.82
60EMA 19.82
120EMA 19.82
250EMA 19.82